| Title: |
Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression. |
| Authors: |
Charalampous, Charalampos1 (AUTHOR), Doucette, Kimberley1,2 (AUTHOR), Chappell, Aimee1,2 (AUTHOR), Vesole, David H.1,2,3 (AUTHOR) david.vesole@hmhn.org |
| Source: |
Leukemia & Lymphoma. Dec2024, Vol. 65 Issue 12, p1901-1904. 4p. |
| Subject Terms: |
*PLASMA cell leukemia, *PLASMA cell diseases, *IMMUNOGLOBULIN light chains, *POSITRON emission tomography computed tomography, *PLASMA cells |
| Abstract: |
The article discusses the use of venetoclax, a BCL-2 inhibitor, in the treatment of primary plasma cell leukemia (PCL) with high BCL-2 expression. PCL is a rare and aggressive form of plasma cell dyscrasias with a poor prognosis. The case study presented in the article shows a patient with primary PCL who achieved a durable complete response to a venetoclax-based induction regimen without autologous stem cell transplant. The study suggests that venetoclax may be an effective and tolerable treatment option for PCL patients, especially those with high BCL-2 expression. Further research is needed to validate these findings and explore new treatment avenues for PCL patients. [Extracted from the article] |
|
Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
